Susquehanna International Group, LLP Biotechnology

Susquehanna International Group, LLP

$688 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
NVO Novo Nordisk A S	$112B	$97.1 Million 0.01% of portfolio	1,406,758	Q2 2025 Reduced 0.58%
REGN Regeneron Pharmaceuticals, Inc.	$59.7B	$86.1 Million 0.01% of portfolio	164,092	Q2 2025 Added 8.34%
MRNA Moderna, Inc.	$10B	$78.6 Million 0.01% of portfolio	2,849,112	Q2 2025 Added 131.88%
ALNY Alnylam Pharmaceuticals, Inc.	$52.9B	$67.9 Million 0.01% of portfolio	208,262	Q2 2025 Added 195.55%
VKTX Viking Therapeutics, Inc.	$3.06B	$54.8 Million 0.01% of portfolio	2,066,651	Q2 2025 Added 23.25%
TGTX Tg Therapeutics, Inc.	$3.94B	$43.5 Million 0.01% of portfolio	1,208,154	Q2 2025 Added 83.15%
CRSP Crispr Therapeutics Ag	$4.42B	$37.5 Million 0.01% of portfolio	769,945	Q2 2025 Added 164.57%
MDGL Madrigal Pharmaceuticals, Inc.	$6.14B	$30.4 Million 0.0% of portfolio	100,322	Q2 2025 Reduced 29.67%
VRTX Vertex Pharmaceuticals Inc	$99.5B	$27.7 Million 0.0% of portfolio	62,209	Q2 2025 Added 51.28%
BBIO Bridge Bio Pharma, Inc.	$7.28B	$27.4 Million 0.0% of portfolio	634,573	Q2 2025 Reduced 14.21%
CYTK Cytokinetics Inc	$3.23B	$23.8 Million 0.0% of portfolio	720,814	Q2 2025 Added 33.7%
BPMC Blueprint Medicines Corp	$7.73B	$23.6 Million 0.0% of portfolio	184,115	Q2 2025 Reduced 55.37%
SWTX Spring Works Therapeutics, Inc.	$2.93B	$22.8 Million 0.0% of portfolio	484,874	Q2 2025 Reduced 22.25%
INSM Insmed Inc	$16.5B	$21.4 Million 0.0% of portfolio	212,222	Q2 2025 Reduced 52.69%
PTCT Ptc Therapeutics, Inc.	$3.24B	$21.1 Million 0.0% of portfolio	431,730	Q2 2025 Added 307.04%
OCUL Ocular Therapeutix, Inc	$961M	$16.6 Million 0.0% of portfolio	1,788,603	Q2 2025 Added 307.02%
VCYT Veracyte, Inc.	$2.06B	$16.5 Million 0.0% of portfolio	608,845	Q2 2025 Added 13.5%
RXRX Recursion Pharmaceuticals, Inc.	$976M	$16.2 Million 0.0% of portfolio	3,205,339	Q2 2025 Added 56.39%
RPRX Royalty Pharma PLC	$15.7B	$15.8 Million 0.0% of portfolio	439,392	Q2 2025 Reduced 67.97%
ARGX Argenx Se	$35.3B	$13.1 Million 0.0% of portfolio	23,790	Q2 2025 Added 1,170.15%
LQDA Liquidia Corp	$1.55B	$12.5 Million 0.0% of portfolio	999,609	Q2 2025 Added 33.14%
AKRO Akero Therapeutics, Inc.	$2.23B	$11.1 Million 0.0% of portfolio	207,754	Q2 2025 Added 15.17%
AXSM Axsome Therapeutics, Inc.	$4.51B	$11.1 Million 0.0% of portfolio	106,021	Q2 2025 Added 104.97%
BEAM Beam Therapeutics Inc.	$1.19B	$10 Million 0.0% of portfolio	587,977	Q2 2025 Added 205.57%
HALO Halozyme Therapeutics, Inc.	$8.95B	$9.49 Million 0.0% of portfolio	182,424	Q2 2025 Added 12.44%
ADMA Adma Biologics, Inc.	$3.29B	$8.83 Million 0.0% of portfolio	484,717	Q2 2025 Added 57.28%
LEGN Legend Biotech Corp	$6.19B	$8.74 Million 0.0% of portfolio	246,146	Q2 2025 Added 148.13%
TECH Bio Techne Corp	$2.07B	$7.44 Million 0.0% of portfolio	144,638	Q2 2025 Added 910.82%
NTLA Intellia Therapeutics, Inc.	$825M	$7.17 Million 0.0% of portfolio	763,981	Q2 2025 Added 78.04%
CORT Corcept Therapeutics Inc	$7.88B	$6.99 Million 0.0% of portfolio	95,211	Q2 2025 Reduced 20.15%
XENE Xenon Pharmaceuticals Inc.	$2.24B	$6.96 Million 0.0% of portfolio	222,352	Q2 2025 New
RVMD Revolution Medicines, Inc.	$3.09B	$6.83 Million 0.0% of portfolio	185,669	Q2 2025 Reduced 23.92%
UTHR United Therapeutics Corp	$13.7B	$6.69 Million 0.0% of portfolio	23,266	Q2 2025 Added 250.34%
URGN Uro Gen Pharma Ltd.	$437M	$6.64 Million 0.0% of portfolio	484,823	Q2 2025 Added 426.84%
SMMT Summit Therapeutics Inc.	$5.17B	$6.38 Million 0.0% of portfolio	299,973	Q2 2025 Added 18.33%
ALT Altimmune, Inc.	$177M	$6.27 Million 0.0% of portfolio	1,619,747	Q2 2025 Added 50.53%
NVAX Novavax Inc	$663M	$5.87 Million 0.0% of portfolio	931,726	Q2 2025 Added 96.44%
CPRX Catalyst Pharmaceuticals, Inc.	$2.09B	$5.86 Million 0.0% of portfolio	270,171	Q2 2025 Added 14.54%
APLS Apellis Pharmaceuticals, Inc.	$2.63B	$5.69 Million 0.0% of portfolio	328,726	Q2 2025 Added 1,014.14%
AVXL Anavex Life Sciences Corp.	$840M	$5.59 Million 0.0% of portfolio	606,667	Q2 2025 Reduced 22.92%
NUVL Nuvalent, Inc.	$3.29B	$5.55 Million 0.0% of portfolio	72,692	Q2 2025 Added 48.48%
JANX Janux Therapeutics, Inc.	$1.01B	$5.31 Million 0.0% of portfolio	229,989	Q2 2025 Reduced 37.66%
INCY Incyte Corp	$18.2B	$5.29 Million 0.0% of portfolio	77,626	Q2 2025 Added 69.14%
RNA Avidity Biosciences, Inc.	$2.41B	$5 Million 0.0% of portfolio	175,943	Q2 2025 Reduced 8.87%
PCVX Vaxcyte, Inc.	$1.78B	$4.97 Million 0.0% of portfolio	152,852	Q2 2025 Reduced 51.98%
IBRX Immunity Bio, Inc.	$989M	$4.89 Million 0.0% of portfolio	1,851,908	Q2 2025 Added 139.43%
RYTM Rhythm Pharmaceuticals, Inc.	$5.51B	$4.88 Million 0.0% of portfolio	77,262	Q2 2025 Reduced 6.89%
ARWR Arrowhead Pharmaceuticals, Inc.	$1.88B	$4.86 Million 0.0% of portfolio	307,745	Q2 2025 Added 6.35%
MNKD Mannkind Corp	$942M	$4.56 Million 0.0% of portfolio	1,219,718	Q2 2025 Reduced 18.58%
ACAD Acadia Pharmaceuticals Inc	$4.12B	$4.34 Million 0.0% of portfolio	201,270	Q2 2025 Reduced 52.69%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.